Overview

* Acadia Q3 2025 revenue grows 11% yr/yr to $278.6 mln

* Net income for Q3 2025 rises to $71.8 mln, reflecting tax benefit

* Company updates 2025 guidance, raising high end for NUPLAZID and DAYBUE sales

Outlook

* Acadia raises 2025 revenue guidance to $1.070 bln-$1.095 bln

* Company expects NUPLAZID sales of $685 mln-$695 mln in 2025

* Acadia forecasts DAYBUE sales of $385 mln-$400 mln for 2025

Result Drivers

* NUPLAZID SALES GROWTH - Driven by 9% volume increase and higher net selling price

* DAYBUE SALES EXPANSION - Boosted by field force expansion and named patient supply programs outside the U.S.

* PIPELINE ADVANCEMENT - Initiation of Phase 2 and Phase 3 trials for new treatments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $278.63

Product mln

Sales

Q3 EPS $0.42

Q3 Net $71.78

Income mln

Q3 $242.88

Operatin mln

g

Expenses

Q3 $44.60

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc ( ACAD ) is $29.00, about 24.7% above its November 4 closing price of $21.85

* The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 35 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)